CA3175703C - Compositions and methods comprising bupropion or related compounds and dextromethorphan - Google Patents

Compositions and methods comprising bupropion or related compounds and dextromethorphan

Info

Publication number
CA3175703C
CA3175703C CA3175703A CA3175703A CA3175703C CA 3175703 C CA3175703 C CA 3175703C CA 3175703 A CA3175703 A CA 3175703A CA 3175703 A CA3175703 A CA 3175703A CA 3175703 C CA3175703 C CA 3175703C
Authority
CA
Canada
Prior art keywords
dextromethorphan
compositions
bupropion
methods
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3175703A
Other languages
English (en)
French (fr)
Other versions
CA3175703A1 (en
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Priority to CA3175703A priority Critical patent/CA3175703C/en
Priority to CA3256217A priority patent/CA3256217A1/en
Publication of CA3175703A1 publication Critical patent/CA3175703A1/en
Application granted granted Critical
Publication of CA3175703C publication Critical patent/CA3175703C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3175703A 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan Active CA3175703C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3175703A CA3175703C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA3256217A CA3256217A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900354P 2013-11-05 2013-11-05
US61/900,354 2013-11-05
CA3175703A CA3175703C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA3154845A CA3154845C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3154845A Division CA3154845C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Publications (2)

Publication Number Publication Date
CA3175703A1 CA3175703A1 (en) 2015-05-14
CA3175703C true CA3175703C (en) 2025-08-05

Family

ID=53042051

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3175703A Active CA3175703C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA3256217A Pending CA3256217A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA3154845A Active CA3154845C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA2929415A Active CA2929415C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3256217A Pending CA3256217A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA3154845A Active CA3154845C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan
CA2929415A Active CA2929415C (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Country Status (12)

Country Link
EP (3) EP3065742A4 (enExample)
JP (5) JP6605485B2 (enExample)
KR (4) KR102264179B1 (enExample)
CN (7) CN113750098A (enExample)
AU (7) AU2014346807B2 (enExample)
CA (4) CA3175703C (enExample)
IL (3) IL298972A (enExample)
MX (3) MX373330B (enExample)
MY (1) MY179696A (enExample)
NZ (1) NZ758428A (enExample)
SG (4) SG10201810888XA (enExample)
WO (1) WO2015069809A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
JP6605485B2 (ja) * 2013-11-05 2019-11-13 アンテシップ バイオベンチャーズ トゥー エルエルシー ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR20170052684A (ko) * 2014-09-14 2017-05-12 아바니르 파마슈티컬스, 인코포레이티드 치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물
JP6602863B2 (ja) * 2014-11-21 2019-11-06 アンテシップ バイオベンチャーズ トゥー エルエルシー ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物
WO2017165845A1 (en) * 2016-03-24 2017-09-28 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US20230225995A1 (en) * 2019-01-07 2023-07-20 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
CN114712357A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合
JP7637150B2 (ja) * 2020-03-30 2025-02-27 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN117100750A (zh) * 2020-07-20 2023-11-24 深圳信立泰药业股份有限公司 一种药物组合物及其应用
JP2023553393A (ja) 2020-12-01 2023-12-21 アンテシップ バイオベンチャーズ トゥー エルエルシー うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン
JP2024503114A (ja) * 2021-01-18 2024-01-24 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ
CN112999350A (zh) * 2021-02-23 2021-06-22 北京斯利安药业有限公司 一种药物组合物、复方制剂及其制备方法与应用
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
EP0980247A1 (en) * 1997-05-07 2000-02-23 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
JP6605485B2 (ja) * 2013-11-05 2019-11-13 アンテシップ バイオベンチャーズ トゥー エルエルシー ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物

Also Published As

Publication number Publication date
CN113797205A (zh) 2021-12-17
MX388666B (es) 2025-03-20
KR102603013B1 (ko) 2023-11-15
AU2019236614C1 (en) 2021-10-14
KR102264179B1 (ko) 2021-06-11
NZ719892A (en) 2021-07-30
MY179696A (en) 2020-11-11
KR20230148385A (ko) 2023-10-24
CN113750098A (zh) 2021-12-07
CA2929415A1 (en) 2015-05-14
CA2929415C (en) 2023-01-03
SG10201911816XA (en) 2020-01-30
AU2025230795A1 (en) 2025-10-02
AU2018203638A1 (en) 2018-06-14
EP3981403A1 (en) 2022-04-13
SG10201911808QA (en) 2020-01-30
JP2016535786A (ja) 2016-11-17
IL283760B1 (en) 2023-01-01
IL245504A0 (en) 2016-06-30
NZ758432A (en) 2021-07-30
AU2019275593B2 (en) 2021-01-28
NZ758431A (en) 2021-07-30
CA3175703A1 (en) 2015-05-14
AU2023203438B2 (en) 2025-06-26
CA3256217A1 (en) 2025-10-30
JP6927601B2 (ja) 2021-09-01
EP3981404A1 (en) 2022-04-13
AU2014346807A1 (en) 2016-05-19
JP6605485B2 (ja) 2019-11-13
AU2019236614B2 (en) 2021-07-15
JP2025175199A (ja) 2025-11-28
IL283760B2 (en) 2023-05-01
JP2020023543A (ja) 2020-02-13
AU2021202497B2 (en) 2023-03-02
JP2021169527A (ja) 2021-10-28
KR20220054909A (ko) 2022-05-03
EP3065742A4 (en) 2017-04-05
CN106163522A (zh) 2016-11-23
CN110327338A (zh) 2019-10-15
SG10201810888XA (en) 2019-01-30
IL283760A (en) 2021-07-29
CN110279682A (zh) 2019-09-27
AU2018203638B2 (en) 2019-07-18
IL298972A (en) 2023-02-01
WO2015069809A1 (en) 2015-05-14
MX2020004075A (es) 2021-12-10
AU2023203438A1 (en) 2023-07-06
EP3065742A1 (en) 2016-09-14
CA3154845A1 (en) 2015-05-14
JP2023129646A (ja) 2023-09-14
CN110251517A (zh) 2019-09-20
KR20160070158A (ko) 2016-06-17
AU2018203638C1 (en) 2019-10-24
AU2019275593A1 (en) 2020-01-02
NZ758425A (en) 2021-07-30
NZ758428A (en) 2021-07-30
KR20210068157A (ko) 2021-06-08
CN113750099A (zh) 2021-12-07
IL245504B (en) 2021-06-30
AU2019236614A1 (en) 2019-10-17
CA3154845C (en) 2023-02-28
MX2016005867A (es) 2016-07-15
MX373330B (es) 2020-05-04
SG11201603391XA (en) 2016-05-30
AU2021202497A1 (en) 2021-05-27
MX2021015234A (es) 2022-05-26
AU2014346807B2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CA3175703C (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12015502263A1 (en) Composition for preventing or treating hangover
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
EA201690445A1 (ru) Лечение рака
EA201690446A1 (ru) Лечение множественной миеломы
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
IN2013MU03428A (enExample)
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
HK1228779A1 (zh) 包含安非他酮或相关化合物和右美沙芬的组合物和方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921